Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Goodwin said its Paris private equity team advised LFPI on acquiring a majority stake in CBM, a distributor of spare parts for buses and coaches. The firm said the transaction is intended to support CBM’s organic growth, international expansion and acquisition strategy.
Goodwin said its life sciences team advised City Therapeutics on pricing an upsized initial public offering expected to raise approximately $200 million before expenses. The firm said City is developing RNA interference therapies and that all shares in the offering are being sold by the company.
Goodwin said its private equity team advised Keensight Capital and Bedfont Scientific on their acquisition of medical diagnostic equipment company coVita. The firm said the acquisition gives Bedfont a U.S. base for clinical research and localized distribution, training and technical support.
Goodwin said its Paris investment funds team advised Jolt Capital on acquiring Mirova’s private equity business, comprising the MEAC and MILE funds. The firm said both funds’ teams and investment portfolios will transfer to Jolt, which will assume management while retaining their investment strategies and impact objectives.
Goodwin said its Paris private equity team advised Libeo on its acquisition by Shine, part of Cegid Group. The firm described Libeo as a French platform for invoice management, expenses and payments that uses artificial intelligence in control, approval, procurement and payment workflows.
Goodwin announced that its life sciences team had advised Dualitas Therapeutics on a research collaboration and licensing agreement with Roche. The firm said Dualitas would receive $36.5 million upfront, with potential additional payments bringing the deal value to $1 billion, plus royalties, for work on antibodies targeting immunology and inflammation diseases.
Goodwin announced that four partners had been included in Forbes’ third annual Top 250 Lawyers in America list. The firm said the selection involved nominations, outreach, recommendations and editorial review, and identified honorees working in patent litigation, antitrust, financial-services disputes and mergers and acquisitions.
Goodwin announced that it had advised Marea Therapeutics on its acquisition by Lisata Therapeutics. The firm said Lisata also entered an agreement for a private placement expected to raise approximately $225 million before expenses, and described the acquisition as a stock-for-stock transaction involving the companies’ biotechnology businesses.
Goodwin announced that its technology team had advised fusion-energy company Helion on the final close of a $500 million Series G financing. The firm described the round as upsized and oversubscribed and said proceeds would support Helion’s work toward commercial deployment of fusion-generated electricity.